

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumention Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1477)**

**VOLUNTARY ANNOUNCEMENT**  
**PRIMARY ENDPOINTS ACHIEVED**  
**IN THE PHASE III CLINICAL TRIAL OF OT-502 IN CHINA**

This announcement is made by Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that, OT-502 (DEXYCU<sup>®</sup>, dexamethasone implant), a new drug for the treatment of postoperative inflammation indication, has successfully achieved the expected primary efficacy endpoints of its phase III clinical trial, i.e., the treatment group receiving the dexamethasone implant exhibited a notably higher proportion of subjects with anterior chamber cells clearing (ACC grade 0) compared to the placebo group by day 8, demonstrating the safety and efficacy of the product in managing post-cataract inflammation. The Company expects to submit the new drug application (NDA) of OT-502 to the Center for Drug Evaluation of National Medical Products Administration of China (中國國家藥品監督管理局藥品審評中心) in the near future.

OT-502 (dexamethasone implant) is a single-dose, sustained-release solution of dexamethasone, a corticosteroid, for the treatment of postoperative inflammation. To date, OT-502 is the first and only single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation that was approved by the United States Food and Drug Administration. The Group is developing OT-502 as a potential first-in-class treatment for postoperative inflammation associated with cataract surgery in China. The phase III clinical trial of OT-502 is designed to be a randomized, double-masked, placebo-controlled, parallel-group, multi-center clinical and pharmacokinetic study to evaluate the efficacy and safety of 9% dexamethasone implant in the treatment of post-cataract surgery inflammation, which has completed the patient enrollment in China in November 2023.

**Cautionary Statement:** The Company cannot guarantee that it will ultimately commercialize OT-502 (DEXYCU<sup>®</sup>, dexamethasone implant) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Ocumention Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, April 15, 2024

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.*